Hormone Therapy Market Report 2026

The hormone therapy market size has grown strongly in recent years. It will grow from $20.9 billion in 2025 to $22.44 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to rising prevalence of hormonal disorders, growing awareness of hormone replacement therapy, increased diagnosis rates of hypothyroidism, expansion of hospital pharmacy networks, availability of low-cost generic hormones.

The hormone therapy market size is expected to see strong growth in the next few years. It will grow to $29.93 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to aging global population, growth in menopause-related treatments, increasing focus on quality of life therapies, expansion of online pharmacies, ongoing innovation in hormone delivery systems. Major trends in the forecast period include rising adoption of personalized hormone regimens, growing demand for bioidentical hormones, expansion of hormone therapy in aging populations, increased use of combination hormone therapies, shift toward convenient and long-acting formulations.

The growing elderly population is expected to drive the growth of the hormone therapy market in the coming years. Elderly individuals, typically considered those in the later stages of life, often face age-related health conditions that can benefit from hormone therapy. Hormone treatments in this population aim to correct hormonal imbalances and manage specific aging-related disorders. For example, in July 2024, the UK Parliament reported that the UK population is projected to reach 70 million by 2026, with 19% of people aged 65 or older in 2022 - a figure expected to rise to 27% by 2072. Therefore, the increasing number of elderly individuals is fueling demand in the hormone therapy market.

Leading companies in the hormone therapy market are developing innovative solutions, such as direct-to-consumer telehealth models, to improve accessibility and convenience for patients. This telehealth model allows patients to receive hormone therapy services remotely, eliminating the need for traditional in-person consultations. For example, in September 2023, LifeMD, a U.S.-based telehealth company, partnered with ASCEND Therapeutics, a U.S.-based pharmaceutical company, to launch an integrated direct-to-consumer telehealth model for hormone therapy, focusing on EstroGel (estradiol gel) for alleviating menopausal symptoms. Through this partnership, patients can access LifeMD’s telehealth services directly via the EstroGel website, consult licensed healthcare providers, receive prescriptions, and arrange home delivery. By streamlining access and reducing barriers such as long wait times, the initiative aims to improve health outcomes for women seeking menopause treatment.

In January 2024, Biote Corp, a U.S.-based provider of personalized hormone-optimization and therapeutic wellness solutions, acquired Asteria Health for US$ 8.5 million. This acquisition strengthened Biote’s vertical integration by adding 503B manufacturing capacity, securing its supply chain, and improving operational efficiency. Asteria Health, a U.S.-based company, operates an FDA-registered 503B outsourcing facility specializing in the compounding of bioidentical hormones for Biote-certified clinics.

Major companies operating in the hormone therapy market are Abbott Laboratories, Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche, Merck KGaA, Mylan NV, Novartis AG, Novo Nordisk AS, Pfizer Inc., Abbvie Inc., Teva Pharmaceutical Industries Ltd., Perrigo Company Plc., Cipla Inc., Lupin Limited, Sun Pharmaceuticals Industries Ltd., Hikma Pharmaceuticals PLC., Johnsons & Johnsons Services Inc., Boehringer Ingelheim International GmbH, Sanofi S.A., AstraZeneca plc, TherapeuticsMD Inc., Amgen Inc., Genentech Inc., Dr. Reddy's Laboratories Ltd, Allergan PLC, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited.

North America was the largest region in the hormone therapy market in 2025. The regions covered in the hormone therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hormone therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the hormone therapy market by increasing the cost of imported active pharmaceutical ingredients, excipients, and specialized manufacturing equipment, thereby affecting production economics and pricing. These impacts are most evident across estrogen, thyroid, and growth hormone replacement segments, with Asia-Pacific and Europe being particularly affected due to their reliance on cross-border pharmaceutical supply chains. Higher tariffs have also pressured hospital and retail pharmacy channels by narrowing margins and limiting affordability in price-sensitive markets. However, tariffs have encouraged localized manufacturing, supply chain diversification, and regional API sourcing, supporting long-term resilience and domestic production growth in select regions.

The hormone therapy market research report is one of a series of new reports that provides hormone therapy market statistics, including hormone therapy industry global market size, regional shares, competitors with a hormone therapy market share, detailed hormone therapy market segments, market trends and opportunities, and any further data you may need to thrive in the hormone therapy industry. This hormone therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hormone therapy is a type of treatment that modifies, suppresses, or increases specific hormones in the body. It is used to manage hormonal imbalances, including conditions such as hypothyroidism and others.

The main types of hormone therapy include estrogen hormone replacement, growth hormone replacement, thyroid hormone replacement, and testosterone replacement. Estrogen hormone replacement therapy involves administering estrogen to increase the body’s estrogen levels. These therapies are delivered via oral, parenteral, and other routes for conditions such as menopause, hypothyroidism, growth hormone deficiency, and more. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The hormone therapy market includes revenues earned by entities by providing hormone therapies such as insulin therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.